And right now, multiple potential catalysts could once again fuel a vertical chart move in the near term for ALBT. They are:
No. 1 ALBT Potential Catalyst - Game-Changing Patent News Has So Far Gone Under The Radar...
Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Patent Jointly Filed with the Massachusetts Institute of Technology (MIT)
FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
“We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.”
“The QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT, can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications including mitigation of the 'cytokine storm' associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies,” concluded Dr. Jin.
Read the full article here.
No. 2 ALBT Potential Catalyst - A Low Float Could Allow For Explosive Volatility (Daily)
According to the Yahoo Finance website, ALBT has a low float.
The website reports this profile to have approximately 3.22Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news early this year help provide a near term spark?
No. 3 ALBT Potential Catalyst - Company's Fusion Gene Map Technology Seen As Major Breakthrough
Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.
“Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The first diagnostic prototype is expected to enter clinical study and regulatory filing stage during Q3 of 2023. The fusion gene map technology also provides an unprecedented opp. to identify and validate fusion gene products as potential novel therapeutic targets. Additionally, this gives us an opp. to expand Avalon’s R&D pipeline and intellectual property portfolio.”
Read the full article here.
ALBT Recap: These Potential Catalysts Could Fuel A Vertical Move For This 5X Champ
No. 1 - Game-Changing Patent News Has So Far Gone Under The Radar...
No. 2 - A Low Float Could Allow For Explosive Volatility (Daily)
No. 3 - Company's Fusion Gene Map Technology Seen As Major Breakthrough
Coverage is officially reinitiated on ALBT. When time permits, do this: